Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
OGEN vs PTN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
PTN Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–3 Matrix Metrics)
PTN Overall Winner
6-Pillar Tally: OGEN 1 – 4 PTN (1 Tie)
Matrix Metrics: OGEN 3 – 7 PTN
As of Nov 16, 2026, Palatin Technologies, Inc. (PTN) is the stronger overall head-to-head candidate over Oragenics Inc. (OGEN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). OGEN carries a Unified Composite Score of 38.8/100 (SELL) at $0.20 (N/M Forward P/E, 0.0% operating margin), whereas PTN carries 31.5/100 (SELL) at $6.12 (42.9x Forward P/E, -65.7% operating margin).
- Composite vs. Pillar Nuance: While OGEN currently prints a higher short-term Unified Composite Score (38.8/100 SELL vs. PTN 31.5/100 SELL), PTN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-65.7% vs. 0.0% operating margin) and revenue trajectory (-80.1% vs. -91.3% YoY).
- Defensive Composite Rating Caution: Although PTN compares more favorably head-to-head, both OGEN (38.8/100 SELL) and PTN (31.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
- Technical & Structure Timing Caution: OGEN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 14.1); meanwhile PTN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About OGEN vs PTN
OGEN
Oragenics Inc.
$0.20
-1.49% 1D
Market Cap
$906,903
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.19β · 153% Vol
Unified Composite Score
38.8
SELL
Tech 25.0
Fund 46.0
Flow 50.0
Mom 75.0
Weinstein Technical Phase
Markdown · Sell / avoid
PTN
Head-to-Head Winner
Palatin Technologies, Inc.
$6.12
-1.69% 1D
Market Cap
$11.1M
TTM Revenue
$13M
Forward P/E
42.9x
Beta / 30D Vol
0.87β · 106% Vol
Unified Composite Score
31.5
SELL
Tech 15.0
Fund 30.0
Flow 50.0
Mom 40.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (OGEN 1 – 4 PTN)
1. Valuation Multiples
PTN
Forward P/E
N/M
42.9x
Trailing P/E
N/M
42.9x
PEG Ratio
N/M
1.62x
EV / Revenue
N/M
0.1x
2. Growth & Scale
PTN
Revenue Growth (YoY)
-91.3%
-80.1%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$13M
Market Cap
$906,903
$11.1M
3. Profitability & Quality
OGEN
Gross Margin
N/A
6.2%
Operating Margin
0.0%
-65.7%
Net Profit Margin
0.0%
-63.5%
Return on Equity (ROE)
-1307.1%
-877.5%
4. Balance Sheet & Cash Flow
PTN
Cash Generation (TTM)
N/A
-$15M
Cash Flow Margin
N/A
-113.6%
Net Cash / Leverage
$1.94 Book/Sh · -1307.1% ROE
$9.9M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
PTN
OpEx & R&D Intensity
N/A
71.9% of Rev ($9.5M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: OGEN (3) vs PTN (7)| Institutional Metric | OGEN | PTN | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $906,903 | $11.1M | PTN | |
| Trailing P/E Ratio | N/M | 42.9x | PTN | |
| Forward P/E Ratio | N/M | 42.9x | PTN | |
| Revenue Growth (YoY) | -91.3% | -80.1% | PTN | |
| Operating Margin (TTM) | 0.0% | -65.7% | OGEN | |
| Net Profit Margin | 0.0% | -63.5% | OGEN | |
| Return on Equity (ROE) | -1307.1% | -877.5% | PTN | |
| 52-Week Range Position | 3% ($0–$1) | 6% ($5–$31) | PTN | |
| Beta / 30D Volatility | 1.19β · 153% Vol | 0.87β · 106% Vol | PTN | |
| Unified Institutional Score | 38.8 / 100 (SELL) | 31.5 / 100 (SELL) | OGEN | |
| Trailing 12M Revenue (USD) | N/A | $13M | Scale | |
| Gross Profit Margin (TTM) | N/A | 6.2% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | 1.62x PEG · 0.1x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | N/A ($1.94 Book/Sh · -1307.1% ROE) | -$15M ($9.9M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
PTN +56.21 pp
3M Horizon
PTN +22.02 pp
6M Horizon
PTN +5.52 pp
1Y Horizon
PTN +39.34 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | OGEN Revenue | PTN Revenue | OGEN Op. Margin | PTN Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $70M | N/A | 38.6% | PTN |
| FY2019 | N/A | $60M | N/A | 59.3% | PTN |
| FY2020 | N/A | $0M | N/A | -20007.6% | PTN |
| FY2021 | $0M | N/A | -18130.3% | N/A | OGEN |
| FY2022 | $0M | $0M | -10964.6% | -2491.6% | PTN |
| FY2023 | $0M | $0M | -55519.9% | -668.7% | PTN |
| FY2024 | N/A | $0M | N/A | -501.0% | PTN |
| FY2026 | N/A | $10M | N/A | -65.7% | PTN |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
OGEN
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact OGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
PTN
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact PTN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
OGEN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
PTN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
71.9% of Rev ($9.5M)
90D Engineering Disclosures
0 Published
Investor FAQ OGEN vs PTN Key Questions & Quantitative Answers
As of Nov 16, 2026, Palatin Technologies, Inc. (PTN) is the stronger overall head-to-head candidate over Oragenics Inc. (OGEN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). OGEN carries a Unified Composite Score of 38.8/100 (SELL) at $0.20 (N/M Forward P/E, 0.0% operating margin), whereas PTN carries 31.5/100 (SELL) at $6.12 (42.9x Forward P/E, -65.7% operating margin). Composite vs. Pillar Nuance: While OGEN currently prints a higher short-term Unified Composite Score (38.8/100 SELL vs. PTN 31.5/100 SELL), PTN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-65.7% vs. 0.0% operating margin) and revenue trajectory (-80.1% vs. -91.3% YoY). Defensive Composite Rating Caution: Although PTN compares more favorably head-to-head, both OGEN (38.8/100 SELL) and PTN (31.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: OGEN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 14.1); meanwhile PTN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
PTN leads the Growth & Scale pillar: OGEN posts -91.3% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PTN at -80.1% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (6.2% gross margin, -65.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2026), OGEN cumulative revenue shifted N/A while PTN shifted -85.7%. In operating R&D and SG&A reinvestment, OGEN deploys N/A (0 90-day corporate R&D disclosures) versus 71.9% of Rev ($9.5M) (0 disclosures) for PTN.
PTN screens cheaper on headline valuation multiples. OGEN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas PTN trades at 42.9x Forward P/E, 42.9x Trailing P/E, 1.62x PEG, and 0.1x EV/Revenue (-113.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OGEN (-1307.1% ROE) versus PTN (-877.5% ROE) capital efficiency.
In options market volatility and institutional positioning, OGEN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 153% Vol realized risk). By comparison, PTN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.87β · 106% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
PTN vs OGEN · Reverse Pair
OGEN vs VTVT
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal